Current stock page

Financial Data

RAPP Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

RAPPRapport Therapeutics, Inc. Common Stock

Healthcare / Biotechnology

Low Priority

Relative Laggard

BearishEdge 3/10
$26.15+$0.30 (+1.16%)

Latest quote

  • Momentum
    33
  • Value
    42
  • Quality
    57
  • Risk resilience
    39
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$0$0$20M$0$0$0$0$0
Gross Profit$0$0$20M$0$0$0$0$0
Operating Income-$44.09M-$60.81M-$24.22M-$38.51M-$29.99M-$29.5M-$27.11M-$23.52M
Net Income-$40.24M-$56.62M-$19.86M-$33.76M-$26.93M-$26.73M-$24.06M-$19.98M
EPS-$0.84-$1.19-$0.42-$0.72-$0.71-$0.75-$0.68-$0.55
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$41.63M-$41.46M-$13.06M-$24.7M-$17.47M-$25.07M-$20.24M-$14.45M
Capital Expenditure$0-$78K-$86K-$169K-$134K-$22K-$291K-$226K
Free Cash Flow-$41.63M-$41.53M-$13.15M-$24.87M-$17.6M-$25.09M-$20.53M-$14.67M
Net Cash Provided By Operating Activities-$41.63M-$41.46M-$13.06M-$24.7M-$17.47M-$25.07M-$20.24M-$14.45M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$418.56M$458.98M$497.6M$512.43M$535.32M$285.5M$302.05M$314.93M
Total Debt$9.39M$10.11M$10.8M$11.48M$11.87M$11.86M$7.84M$1.48M
Cash And Cash Equivalents$74.75M$63.61M$78.06M$52.65M$251.36M$55.07M$57.6M$56.81M
Total Liabilities$27.37M$36.06M$26.09M$27.78M$23.71M$21.98M$16.22M$9.51M
Total Stockholders Equity$391.19M$422.93M$471.51M$484.65M$511.62M$263.51M$285.84M$305.43M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio2.94.7642.871.882.070.72—
P/S ratio62.46———————
Debt To Equity0.020.020.020.020.020.050.030
Free Cash Flow Yield-10.70%-4.82%-4.28%-6.33%-8.10%-14.07%-33.63%—
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio2.94.7642.871.882.070.72—
P/S ratio62.46———————
Return On Equity-38.46%-32.43%-22.75%-23.00%-19.10%-33.51%-27.88%-25.64%
Debt To Equity0.020.020.020.020.020.050.030

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-8.25x
Pb3.19x
EPS Growth Yoy-18.31%
Gross Margin100.00%
Operating Margin-838.08%
ROE-34.00%
ROIC-41.84%
Debt To Equity0.02
FCF Yield-9.66%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$26.15
Volume316,121
RSI (14)44.91
MACD-1.59
MACD signal-2.21
MACD histogram0.62
ADX (14)31.38
SMA (50)$31.93
SMA (200)$35.59
ATR (14)$2.10
Historical volatility (annualized)111.11%
Volume (20-day average)1.63M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score39/100
Beta1.27
Annual volatility62.34%
Max Drawdown-57.14%
Sharpe Ratio0.35
VaR (95%, 1-day)-5.80%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

RAPP Financial Data FAQ

What is Rapport Therapeutics, Inc. Common Stock's revenue?

Rapport Therapeutics, Inc. Common Stock's revenue is one of the core financial data points for RAPP. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Rapport Therapeutics, Inc. Common Stock's revenue growing?

Revenue growth shows whether Rapport Therapeutics, Inc. Common Stock is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is RAPP's EPS?

RAPP's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Rapport Therapeutics, Inc. Common Stock's net income?

Rapport Therapeutics, Inc. Common Stock's net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Rapport Therapeutics, Inc. Common Stock generate?

Free cash flow shows how much cash Rapport Therapeutics, Inc. Common Stock generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Rapport Therapeutics, Inc. Common Stock have?

Cash and debt help frame RAPP's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.